Yellow fever revaccination guidelines change - A decision too feverish?

Clinical Microbiology and Infection

Volumn 19, Issue 10, 2013, Pages 885-886

  Grobusch, M P ^a   Goorhuis, A ^a   Wieten, R W ^a   Verberk, J D M ^a   Jonker, E F F ^b   van Genderen, P J J ^c   Visser, L G ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Harbour Hospital   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISERUM; NEUTRALIZING ANTIBODY; YELLOW FEVER VACCINE;

ARTICLE; ASSAY; CELL CULTURE; DILUTION; FLAVIVIRUS; HEALTH CARE POLICY; HUMAN; IMMUNITY; IMMUNIZATION; IMMUNOLOGICAL MEMORY; INNATE IMMUNITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTECTION; REVACCINATION; RISK; SYSTEMATIC REVIEW; VACCINATION; YELLOW FEVER; YELLOW FEVER FLAVIVIRUS;

HUMANS; IMMUNIZATION, SECONDARY; PRACTICE GUIDELINES AS TOPIC; WORLD HEALTH ORGANIZATION; YELLOW FEVER; YELLOW FEVER VACCINE;

EID: 84884717708     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12332     Document Type: Article

References (3)

1. World Health Organization. Meeting of the Strategic Advisory Group of Experts on Immunization, April 2013 - conclusions and recommendations. Wkly Epidemiol Rec 2013; 88: 201-216.
2. SAGE Working Group. Background Paper on Yellow Fever Vaccine. Geneva: WHO, 2013.
3. World Health Organization. Meeting of the Strategic Advisory Group of Experts on Immunization, October 2003. Wkly Epidemiol Rec 2003; 78: 349-360.